Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05241834 | A Study of LOXO-260 in Cancer Patients With a Change in a Particular Gene (RET) That Has Not Responded to Treatment | PHASE1 | ACTIVE NOT_RECRUITING | 70 | — | — | Mar 23, 2022 | Jun 1, 2026 | Sep 4, 2025 | 16 | United States, France |
DLT rate
| Arm | Type | Description |
|---|---|---|
| Phase 1A: LOXO-260 Dose Escalation | EXPERIMENTAL | LOXO-260 administered orally |
| Phase 1B: LOXO-260 Dose Expansion | EXPERIMENTAL | LOXO-260 administered orally |
| Name | Type | Description |
|---|---|---|
| LOXO-260 | DRUG | Oral |
Inclusion Criteria: * Must be ≥ 18 years of age at the time of signing the informed consent (Phase 1a and Phase 1b). Patients 12 years and older may be enrolled in Phase 1b for countries and sites where approved. * Must have evidence of a previously documented RET fusion (solid tumors) or RET mutat...